The efficacy of low-dose macrolides for severe asthma in clinical practice

The efficacy of low-dose macrolides for severe asthma in clinical practice - The efficacy of low-dose macrolides for severe asthma in clinical practice

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000043310

Enrollment

385

Registered

2021-02-12

Start date

2020-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

asthma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Asthma patients continuously treated from 2018/3/1 to 2020/9/30 in the department of Respiratory Medicine in National Center for Global Health and Medicine. 2) Asthma patients who received treatment equivalent to Global Initiative for Asthma (GINA) Step 4/5. 3) Asthma patients whose asthma exacerbations requiring systemic steroid was retrospectively trackable in their medical records.

Exclusion criteria

Exclusion criteria: 1) Asthma patients who started or discontinued macrolides for their asthma during 2018/3/1-2020/9/30. 2) Other unsuitable conditions

Design outcomes

Primary

Measure	Time frame
The number of annual exacerbations before and after the administration of long-term macrolide therapy	—

Countries

Japan

Contacts

Public ContactNaoko Nagano

National Center for Global Health and Medicine Department of Respiratory Medicine

matsunao28@yahoo.co.jp03-3202-7181

Outcome results